Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Bonesupport, Audiocast, Q3'25

By Inderes10/23/2025, 8:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:01 - 00:23

Welcome to BONESUPPORT Q3 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants can ask questions by dialing the Pound Key followed by five on their telephone keypad. Now, I will hand the conference over to CEO Torbjörn Sköld and CFO Håkan Johansson. Please go ahead.

Torbjörn Sköld
00:24 - 03:14

Thank you, Operator. Welcome, everyone, to Bonesupport's Q3 2025 results call. My name is Torbjörn Sköld, and since September 1st, I'm the CEO of BONESUPPORT HOLDING AB. With me here today is our CFO, Håkan Johansson. And together, the two of us will use the next 25 minutes to guide you through the Q3 report and then open the line for any questions. Before starting the presentation, I would like to draw your attention to the disclaimers covering any forward-looking statements that we will make today. Next slide please. Q3 was another strong quarter with solid execution across the business. Net sales came in at 294 million, corresponding to a growth of 24% compared to Q3 2024. Sales growth at a constant exchange rate was 34%, showing that there's a continued strong currency impact on our figures for the quarter. Our operating results, excluding incentive program effects, were 79 million. Corresponding to an adjusted operating margin of 27%. Reported operating results were 65 million, and we saw strong cash generation with operating cash flow reaching 71 million, leading to a cash position at the end of the quarter of 379 million. One highlight in the quarter was the publication of the long-awaited CeraHip study, which now kicks off our market penetration efforts in this market segment. Revision arthroplasty. We will look deeper into this later in the presentation. We continue to see strong traction for CERAMENT G in the US, where both new accounts and increased use among current users contributed to the strong progress. CERAMENT G sales in the US reached 192 million for the quarter. Furthermore, the proposed NTAP for Cerament G in open trauma has now been confirmed, along with a 6% general increase in segment-relevant DRG codes by CMS for orthopedics. So all in all, an eventful and a successful quarter. As I've transitioned into my new role and reflect on the business, I find our strategy sound and the business is developing very well. What really stands out is the solid evidence base supporting the CERAMENT platform and the significant long-term opportunity of CERAMENT globally in several clinical segments. This spring, we're planning to host a Capital Markets Day, where we'll share a structured overview of our key initiatives and our path forward. We'll follow up with more details and the official date later.

Operator
03:14 - 03:22

So what is your moderator speaking? We're having some technical issues, but we are going to try to get the speakers back as soon as possible.

Torbjörn Sköld
03:26 - 03:35

So the speakers have connected again. Can the moderator please confirm whether the sound and technology are up again?

Operator
03:36 - 03:38

Yes, everything is great.

Torbjörn Sköld
03:39 - 03:40

Thank you very much.

Operator
03:40 - 03:46

Thank you, Moderator. Moderator, can you please inform us? How long did you listen to us?

Torbjörn Sköld
03:47 - 03:56

We came to. You were at the third slide in the third quarter report.

Operator
03:57 - 10:07

Okay. I assume that we have gone through slide three, and we will move over to the sales development. This chart shows the last 12 months' sales in Swedish krona by quarter since 2019, in stacked bars. By region and product category. As you can see, the launch momentum for CERAMENT in the US is exceptionally strong. However, in the last two quarters, we've seen a strong influence from the US dollar to Swedish krona depreciation. Last 12 months' growth in Q3 of 37% in the graph corresponds to an even stronger 41% at constant exchange rates. So most of this quarter-over-quarter slowdown in the last 12 months' sales is due to the strong currency impact. CERAMENT BVF's last 12 months dropped 2% year over year in constant currency. In total, the antibiotic-eluting segment grew by 59% over the last 12 months in the quarter in constant currency. Next slide please. There was some general variability during the quarter due to the usual stop-and-go dynamics, reflecting the strong pace of new customer recruitment over the past 6 to 8 months. As part of our mission to modernize an outdated standard of care in the US, we have successfully opened one market segment after another. We started with foot and ankle. Then we followed with trauma and now we're moving into revision arthroplasty. Revision arthroplasty and the subset segment of periprosthetic joint infections are areas we have not specifically focused on in the past. Each year, approximately 1.5 million primary joint replacements are performed in the US, with just over 70,000 revision procedures requiring bone graft. The surrogate results are groundbreaking. Although the study is not very large, patients have been followed for an average of 3.3 years with no infections reported. I'll speak more about CeraHip on the next slide. We have expanded our US organization, and we plan to recruit additional team members with specialized expertise in revision arthroplasty to support the market entry and the medical education programs. Several distributors are now in place to begin engaging with spine surgeons. Some of these distributors are already our partners today on the extremity side, while others represent new collaborations. The spine segment is new for us, and we will begin generating clinical data during 2026 to establish a foundation for further market penetration. We've also made strong progress in evaluating and preparing the regulatory pathway for introducing CERAMENT G into the spine segment. We have reached a stage where guidance from the FDA on the regulatory path is required. We plan to meet with the FDA at the beginning of 2026. The path forward will be shared and communicated at the Capital Markets Day this spring in 2026. The team has been working diligently on assembling data in response to FDA's inquiry about CERAMENT V, and we expect to send in the Supplementary Data Pack in November. The material relates mostly to clarifications and ensuring that the evidence is presented in a manner that the FDA specifically requires as a pioneer. Technology. There's no template for how to bring forward the evidence. The thoroughness of the process testifies to the rigor of solid data required to qualify a product into the unique category of antibiotic eluting bone graft, and we should remember that this category is defined by another product, namely CERAMENT G. So let's turn to Europe. Next slide please. The third quarter typically shows some volatility due to seasonal factors. Additionally, the contraction and disruption in Germany have persisted as anticipated. Sales in Europe came in at 48 million, representing 5% year-over-year growth and 7% at constant exchange rates. Hybrid markets in Southern Europe, Australia, and Canada are performing strongly. We're beginning to see positive traction from the investments made during the first half of 2025, reflected in improved sales performance in the UK. The previously announced prioritization of hip and knee surgeries is gradually restoring procedure volumes, which bodes well for the future of BONESUPPORT in the UK. However, the pace of recovery varies by region and is largely dependent on staffing levels. During the quarter, the European Bone and Joint Infection Society held its annual meeting. Several podium presentations and posters highlighted the efficacy of CERAMENT and CERAMENT in single-stage procedures, and demonstrated improvements in patient outcomes. A poster presentation by Doctor Miller from Charité, showcasing results from the surrogate study, attracted significant interest, and a large audience will review the detailed findings from the now published study on the next slide. Also, Professor Ferreira, from University Hospital Stellenbosch, presented results from his study involving 403 trauma patients with bone infections. These patients were treated with a single-stage procedure using CERAMENT G or CERAMENT V, after an average follow-up of 11 months. 96% remained infection-free, and there were no amputations. Done this.

Torbjörn Sköld
10:10 - 10:15

Sorry, we're having some technical issues again. The speakers will be back as soon as possible.

Operator
10:20 - 10:42

Meeting of the American Association of Hip and Knee Surgeons occurs in Texas, which last year attracted over 5,100 participants. In fact, our U.S. team is actively preparing for the event at this very moment as it kicks off today. Now, I'll leave a deep dive into the numbers. To Håkan. Welcome, please.

Torbjörn Sköld
10:42 - 17:29

Thank you, Torbjörn. And again, sorry for what seemed to be a day of technical disruptions. Hopefully, everything stabilizes so we can delve into the financials. Net sales improved from 237 million to 284 million, equating to a growth of 24%. Reported sales growth of 34% in constant exchange rates. Torbjörn has already spoken about the solid performance in, especially the US, and the major drivers behind the sales growth, but the weak US dollar somewhat hides a continued strong trajectory in the US. I would like to share the view of sales performance in US dollars. This slide shows the quarterly sales in the US and U.S. dollar. dollar, with continued solid performance quarter to quarter. The growth in dollars for the quarter was 40%. This should be viewed in light of the volatility in sales, with beef sales being 1.7% below the same quarter last year, while CERAMENT G continued to show solid performance with a growth of 59.2%. The contribution from the US segment increased by 31.9 million and amounted to 111.2 million. The improved contribution relates to increased sales despite the effect of increased costs. Sales and marketing expenses during the quarter amounted to 123.6 million, compared with 102.6 million in the previous year, of which sales commissions to distributors and fees amounted to 84.2 million, compared with 65 million in the same quarter last year. From the lower gross, net sales are shown as bars and the gross margin as the orange marker. It can be noted that the gross margin remained stable and strong, around 95% in Europe and the rest of the world. A contribution of 12.5 million was reported, compared with 15.6 million in the previous year. Sales and marketing expenses increased by 4.6 million, including 2 million related to the previously communicated commercial investment in the Euro Booster Programme. Due to the lower growth, the orange marker indicates a minor drop in the gross margin, mainly impacted by market mix. The flat selling expenses, compared with the same quarter previous year, are due to a depreciated US dollar, but also an effect of seasonality. As mentioned previously, the quarter also included 2 million related to the Euro booster programme. R&D remained focused on the execution of strategic initiatives such as the application studies in Spain, procedures, and the market authorization submission for CERAMENT V in the US. These initiatives have been progressing well during the quarter and, among others, are leading up to the launch of our products in Spain later this year. The reported operating result amounted to 65.4 million, despite unfavorable currency effects totaling 5.7 million. And I will come back to this on a following slide. The newly introduced tariffs in the United States are not expected to have a material impact on costs in 2025, due to high safety inventories. The full effect of the current 15% tariff equals a 0.8% impact on US gross margins, and will come gradually with a full effect from 2027. The difference between adjusted and reported operating results are due to costs. Regarding the long-term incentive programs, they amounted to an expense of 13.2 million in the quarter, compared with 7.3 million in the previous year. As you could see from the previous slide. Cash conversion remains solid, with a fifth consecutive quarter of strong cash flow and an increase in cash during the period by 69.3 million despite unfavorable currency effects. With this report, we showcase a strong adjusted operating result and a solid cash flow. We continue to confirm strong operating leverage and business scalability. During the period, the Swedish krona has continued to strengthen against the US dollar. Other operating income and expenses therefore contain foreign exchange gains and losses from the translation of the group's assets and liabilities in foreign currency, amounting to -5.7 million. Simply put, the -5.7 million is mainly driven by the operating assets in the US, such as inventories and trade receivables. These are originally valued in U.S. dollars and measured against the Swedish krona at the end of the quarter. Dollars are translated at quarter end into a much stronger Swedish currency compared to last quarter. The graph on this slide shows, with the gray bars, how the relationship between the US dollar closing rate and the Swedish krona has varied over time. This is read out on the right y-axis. The blue dotted line reads out to the left. The axis shows the reported adjusted operating result. The adjusted operating result, excluding translation exchange effects, is shown as the orange line. The blue dotted line is above the orange line in Q1 2025. The US dollar to SEK rate was 10.02, creating a negative impact of 30 million in Q2. The US dollar dropped down to 9.49, creating a negative impact of 11 million, and in Q3 continued down to 9.41 with a negative impact of 5.7 million. This means that the blue dotted line fell below the orange line for all three quarters. The orange line eliminates the translation exchange effects and provides a more comparable view of the underlying trend in operating profit. In the table below the graph, you can see the FX adjusted operating margin of close to 29% in the period, compared with 23% in the same quarter last year. You can see the FX-adjusted operating margin is close to 29% in the period, compared with 23% in the same quarter last year. And with this, I hand back to you, Torbjörn.

Operator
17:29 - 18:51

Thank you, Håkan. And if we take the last slide. So to summarize Q3 2025 for BONESUPPORT, sales grew 34% in constant currency, reflecting steady and consistent progress. Adjusted operating margin reached 27%. Cash flow remains robust, underscoring the health of the business and its scalability with the publication of the CeraHip study. Strong endorsement from leading surgeons at Charité and detailed procedural guidance for using CERAMENT in revision arthroplasty. We're unlocking a new avenue for market expansion. This marks a significant step forward in our ongoing mission to transform the standard of care. We maintain our guidance on sales growth above 40% in constant exchange rates for the full year 2025. And to conclude, my first period at BONESUPPORT has been as rewarding as it has been intense. I'm convinced that the most exciting part of our journey still lies ahead. Still lies ahead. We will host a Capital Markets Day in the spring of 2026. Lastly, again, apologies for the technical issues that we've had during the call, but now we're happy to open the line for any questions that you might have. We maintain our guidance on sales growth above 40% in constant exchange rates for the full year 2025.

Torbjörn Sköld
18:53 - 19:12

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Eric Cassel from Danske Bank. Please go ahead.

Operator
19:13 - 19:35

Hi, good morning. I probably missed about 70% of what you said. Therefore, please excuse us if we repeat some information. But first, I just want to confirm the sales level for CERAMENT G in the US is approximately 19.9 million USD with 59% organic growth, or is it a completely different figure?

Torbjörn Sköld
19:36 - 19:41

Again, as communicated, it must have reported a 59% growth.

Operator
19:44 - 19:54

Okay, good. First, I then want to ask what you are seeing for trauma now during the initial three weeks since NTAP first emerged in the US.

Torbjörn Sköld
19:57 - 21:04

Again, it has been communicated previously. What we see is a slightly different market dynamic than what we experienced when launching into a bone infection market. So when there is a bone infection, the surgeons are looking for treatment options, and it fits very well with trauma surgeons. It's a bit of a timing issue. If we meet the trauma surgeon and they haven't had a patient come back with a bone infection during the latest weeks or months, it's a harder call to convince them to try the new product. However, if the surgeon has had a patient with a bone infection recently, it's an easier call to convince the surgeon. So I need to start trying. What we see confirms what's been previously communicated. It's a big market potential in trauma, but market penetration to start with will be somewhat slower than when there is a bone infection.

Operator
21:06 - 21:13

Okay. But just specifically on the NTAP, you haven't seen that in and of itself. Have you observed any acceleration in uptake?

Torbjörn Sköld
21:14 - 21:25

Again, the NTAP area is valid from the 1st of October, so it's too early to see whether this has an impact on the penetration of the trauma segment.

Operator
21:26 - 21:43

Okay. Thanks. And then UK down 5.5% year over year. Germany, you mentioned, was performing worse. Is it possible to give any specific numbers on how bad Germany is doing and how much that represents of the European sales?

Torbjörn Sköld
21:43 - 21:54

Again, we have always been cautious to disclose exact numbers on a geographic level. But again, there are structural challenges.

Operator
21:54 - 21:59

The speakers have been disconnected again. But if you have to stay on the line, I hope they will.

Torbjörn Sköld
21:59 - 22:02

Oh, the speakers were not disconnected. We heard them.

Operator
22:03 - 22:04

Germany, you said, was worse.

Torbjörn Sköld
22:05 - 22:07

So do you hear us now, Eric?

Operator
22:08 - 22:10

Yeah, I hear you loud and clear.

Torbjörn Sköld
22:10 - 22:13

Thank you. So again, some of the challenges we face.

Operator
22:22 - 22:24

Okay, now I don't hear the speakers.

Torbjörn Sköld
22:28 - 22:33

Yes, just a second. We're trying to fix the connection problems.

Operator
22:36 - 22:43

So the moderator, where are we now in terms of technology? Because somehow, it feels like things went silent.

Torbjörn Sköld
22:44 - 22:52

Yes. Now you're back. So, Eric, can you repeat your last question so we can go back from there?

Operator
22:52 - 23:10

Yes, sure. It was on Germany; UK down 5.5%. You mentioned Germany was performing worse, and I asked if we could provide more detail about Germany. How much is it down, and how significant is Germany in terms of European sales?

Torbjörn Sköld
23:10 - 23:18

Well, Germany is our second biggest market. So of course, when we have a situation in the market and in markets like Germany, it impacts the totals.

Operator
23:22 - 23:37

Okay. And then just lastly, do you have any visibility on the UK and Germany coming back? You're saying that you're seeing a gradual recovery in the UK, but when can you be back to normal levels or normal growth rates in those markets?

Torbjörn Sköld
23:37 - 24:34

You think again about what is impacting the UK is that it is a market where a substantial healthcare backlog is affecting hospital priorities. Already before the pandemic, there were 5.5 million patients in queue, and that has increased to 8 million patients. And the political priorities have started to reduce that queue, but it's still from a very high level. So again, we will be fighting against hospital priorities from time to time. But in the environment, we start to see that patients who have been waiting for surgeries where CERAMENT is a good fit are gradually coming back. But as Tobin said in the call, it will probably be a slow process for the market to return to a normal and steady situation.

Operator
24:38 - 24:40

All right. Thank you. I'll jump back in queue.

Torbjörn Sköld
24:48 - 24:52

The next question comes from Victor Sundberg from Nordea. Please go ahead.

Operator
24:55 - 24:59

Yes. Thank you for taking my questions; I have two.

Torbjörn Sköld
24:59 - 25:27

So I guess it's not your main product in the US, but I just wanted to dig into the product in the US a bit. We've seen a negative trend in the US for that product over the past couple of quarters, and I just wanted to understand a bit more about what is driving that trend and how to extrapolate this negative growth we’re observing into the coming quarters and into 2026. And then I have another question. But in the environment, we start to see that patients who have been waiting for surgeries where CERAMENT is a good fit are gradually coming back.

Operator
25:29 - 26:29

Again, I think that it's too. So again, as you said, we've seen that the trend has been soft in the latest quarters, but there is also volatility with some quarters showing good product sales. And we see that when we look at sales at the hospital level, there is an underlying volatility in the volumes used. What we also see, and this is important for the longer term, is that with the expanding customer base and with surgeons recruited thanks to CERAMENT, we also see these surgeons starting to use CERAMENT in cases where there is a controlled infection risk, etc. So we remain with a belief that over time the trend will stabilize and growth will. Like we've seen in Europe. Deliver a small organic growth. But the main driver will be our antibiotic-eluting products.

Torbjörn Sköld
26:31 - 26:31

But in the environment, we start to see that patients who have been waiting for surgeries where CERAMENT is a good fit are gradually coming back.

Operator
26:31 - 26:32

But in the environment, we start to see that patients who have been waiting for surgeries where CERAMENT is a good fit are gradually coming back.

Torbjörn Sköld
26:32 - 27:24

And just looking into 2026, if we see substantial cuts to Medicaid as part of the One Big Beautiful Bill act, even if you're not particularly relying on Medicaid directly, I guess hospitals could see an increase in uncompensated care and maybe strained overall budgets due to this. What's your thinking around how hospitals will look at CERAMENT G as it carries a bigger upfront cost? Our feedback, by speaking to some orthopedic surgeons, is that price is the main barrier for wider adoption of CERAMENT in the US. And there's thinking that if major cuts to Medicaid will materialize in 2026. Hospitals might focus even more on price next year, but I also wanted to understand how you plan to mitigate some of those budget headwinds. I guess for next year?

Operator
27:24 - 29:17

Yeah, no. I'll start and Håkan can fill in. So I think the plan to mitigate that is just to follow the BONESUPPORT strategy where we focus on evidence. I think it was very interesting to listen to what was discussed and presented at the European Bone & Joint Infection Society. And it's very clear from those presentations and the discussions that are ongoing. And similarly, at the OTA meeting that happened last week, which is a significant trauma meeting in the US, it's very clear that there is a paradigm shift in the orthopedic market moving away from long systemic antibiotic regimens. In orthopedic surgeries, there is a move towards shorter or even no systemic antibiotic regimens, combining that with local antibiotics, for example, CERAMENT. So that paradigm shift is happening. There is clear evidence already present in the market. The topic is clearly highlighted. And more evidence will come in the future, partly by BONESUPPORT and partly because the market moves in this direction. So, so I think it's nothing new really. It's something that has been happening. It will continue. Anything to add?

Torbjörn Sköld
29:17 - 29:58

I think you've covered that quite well. And again, somehow the pricing is something we encounter as part of the dynamic goal-setting processes we previously referred to. And we have hospitals that are becoming frequent users. And hospital administrations are noticing as well that this drives a certain level of costs. But so far in those discussions, when we come with strong clinical evidence and health economic evidence, these are discussions that we're able to handle and navigate through. So we're confident in the evidence around the technology and the difference it represents to standard care.

Operator
30:00 - 30:01

Thank you very much.

Torbjörn Sköld
30:05 - 30:09

The next question comes from Matthias Madsen from SEB. Please go ahead.

Operator
30:12 - 30:50

Hello. I think I'll take them one by one. First, I think there's quite confident wording around Q4. If I read it correctly. You also reiterated the guidance of at least 4% sales growth. This requires a quite strong finish to the year. I guess very close to 40% organic sales growth, at least, and then acceleration quarter over quarter. So just what brings this confidence and clarity? Yeah. Then if I elaborate on how the start of Q4 has looked for you. That's the first question.

Torbjörn Sköld
30:50 - 31:57

Sure. I'll start with that. More from, let's say, a tactical operational side. And then how can we hopefully back it up with the numbers. As we've reviewed both the US business and the Euro business in detail, the outlook for the quarter appears solid. The fundamentals look very strong from my view in terms of the number of accounts that we have. The penetration in the accounts, and whether we are increasing penetration or losing penetration, is being assessed. So I feel very confident in the numbers at an account level and regional level that we've reviewed. I think, at a very high level, I will also address this. Also, if you look at the comparables Q3 versus Q4, Uh, that also gives me more comfort in the numbers. So yeah, I feel pretty confident in hitting that guidance that we've provided, with 40% sales growth above the prior year on a full-year basis in constant currencies. Okay.

Operator
31:57 - 32:31

Again, I think you covered this quite well earlier on. And again, to bear in mind that if we look at the U.S. Dollar sales in U.S. Dollars. For instance, in the US, Q3 to Q4 last year, Q4 was a bit soft after a strong Q3 and then followed by a strong Q1, etc. We are confident that we. So, moderator, do you hear us?

Torbjörn Sköld
32:31 - 32:36

Are we now over the mobile line instead of over the internet?

Operator
32:37 - 32:39

Yes, now I can hear you. Yes.

Torbjörn Sköld
32:39 - 32:48

So I can hear you.

Operator
32:49 - 33:15

Okay. So what I said is that when we look at, for instance, in the US, in US dollars, last year, Q3 was strong, whereas Q4 was a bit soft. With the underlying momentum we see in the US, we see good opportunities to be well in line with the target we have set for the full year.

Torbjörn Sköld
33:16 - 33:43

Okay, that's perfectly clear. Thank you. Then I have two more. So the next one is the revision arthroplasty segment. I mean, as you said, quite supportive data, to say the least. Sort of, what are the sales volumes in this segment today? And could you talk about what you think is required to sort of achieve a meaningful uptake in this segment?

Operator
33:44 - 35:36

Sure. So I think it's fair to say that currently this is a segment where we've had it on label. It's been on label in the US and it's been on label in Europe. But at the same time, without clinical evidence, very few orthopedic surgeons will pick it up. Very few orthopedic surgeons will adopt it. That's just how orthopedics works. Now, over the last couple of years, the team has worked with Charité, which is, you know, I would argue, among the top three to five hospitals in the world when it comes to revision arthroplasty. They've conducted a study, and to be frank, the results could not have been better. That's the first important step. But to answer your question, our sales in this segment, I would argue, are very, very limited. There is some, but it is very limited. And I think the potential, if we look at the number of procedures that are done in revision arthroplasty in general, and specifically in prosthetic joint infection, which is going to be our primary focus area, those are pretty considerable volume numbers that we have at hand. And what is required is, of course, that we have a sales force that is in front of the customers, who are in the ORs, talking about this and that. We promote the evidence and the application techniques that we already have today. But also, let's be frank, we will continue to invest in education. We will continue to invest in further evidence in this space. And this is work that we've kicked off. And that's something that I foresee will continue for several years ahead, because this is such an interesting and important segment strategically for many years.

Torbjörn Sköld
35:38 - 36:03

Very clear. Then I have a final one. I think it will be quite quick if you take away the effects of the incentive program and sales commission cost, the OpEx looks a bit low. So the question is, is this just usual seasonality or is there anything you would mention here? Sure. So I think it's fair to say that currently, this is a segment where we've had, it's been on label.

Operator
36:05 - 36:21

Primarily, that relates to the normal seasonality. Similarly, outside the US, people tend to have vacations, and during the vacation period, there's a lower level of activity, etc. So you have normal small seasonality.

Torbjörn Sköld
36:22 - 36:23

Thank you very much.

Operator
36:25 - 36:25

Thank you.

Torbjörn Sköld
36:29 - 36:33

The next question comes from Christopher Lilia Berg from Carnegie. Please go ahead.

Operator
36:36 - 36:51

Yeah, thank you. First, just to follow up on the previous question about implant revision. Is this something you think will generate revenues for you already in 2026, or will that be later on?

Torbjörn Sköld
36:51 - 36:53

Revision arthroplasty.

Operator
36:54 - 36:55

Yes.

Torbjörn Sköld
36:56 - 37:07

Yeah, I mean, it will generate revenue in Q4 this year, and it will for sure generate revenue in 2026. If it doesn't, then we are doing something fundamentally wrong.

Operator
37:10 - 37:20

Okay, so do you think you could see a faster uptake in this indication than for open fracture trauma, for example?

Torbjörn Sköld
37:22 - 38:16

That's a really good question. And I don't have any solid data points on that because of my somewhat limited history in BONESUPPORT. But if you think about the segments and how surgeons generally work and how they make decisions and you compare revision arthroplasty, which is an elective procedure, and trauma, especially open trauma, which is acute trauma. So it's not an elective procedure. It's always easier to sell into a segment where elective procedures are involved. So only looking at those sorts of characteristics, you could argue that, well, it should be easier and faster to enter revision arthroplasty than it is for trauma. You could argue that, well, it should be easier and faster to enter revision arthroplasty than it is trauma. So I think there's something in that, which you're absolutely right about. But I have a hard time quantifying it, to be perfectly honest.

Operator
38:18 - 38:32

Okay. And then I don't know whether we missed that due to the technical problems, but did you say anything about the expected launch timing for CERAMENT V in the US?

Torbjörn Sköld
38:34 - 39:31

So CERAMENT V in the US. We follow the plan, so we deliver on the plans. The plans that were previously communicated were that we submit additional data to the FDA in November. That is according to plan. And then we feel comfortable that we have the correct data in place and expect a positive outcome from that review with the FDA. Exactly when the FDA will provide an answer is uncertain. It's hard for us to predict, but typically, historically, what we've seen is that there's a 90-day period following the submission of the supplemental data until an FDA decision is taken. So that's typically the guidance that we give on the CERAMENT V for the US.

Operator
39:33 - 39:46

Great. And then finally, just on R&D costs, should we expect these to be more stable now quarter over quarter or year over year before you start the spine study?

Torbjörn Sköld
39:47 - 40:15

Yeah, I think that is a fair comment. And again, you've seen quite a solid, stable level over the last year, etc., and it's a fair estimate to assume that this level continues as the high activity level remains. But there is no true acceleration until we start a clinical study in preparation for getting EU approval for the spine.

Operator
40:19 - 40:22

Great. Thank you very much. That's all for me.

Torbjörn Sköld
40:28 - 40:33

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Operator
40:34 - 40:54

Yes. Thank you. Good morning. I think most of it has been covered already. Even though there were some technical issues here. So I just want to confirm that I heard it correctly. Did you say that you had CERAMENT sales in the US of $19.9 million in the quarter?

Torbjörn Sköld
40:57 - 41:04

We did not confirm the dollar amount you mentioned. We confirmed that the growth is under control. The exchange rate is 59%.

Operator
41:04 - 41:24

Okay. That's good. And then the number of procedures in the US related to this hip joint infection category. Did I hear it right? 70,000 or?

Torbjörn Sköld
41:26 - 42:19

So what we say is that the number of primary hip and knee arthroplasties, as per previously communicated data from BONESUPPORT, is estimated to be one and a half million. Half a million. The previous number is from BONESUPPORT that has been communicated. Related to the size of that segment is 70,000 for the US only. So those were the numbers that we referred to. So we're not communicating any new numbers on this call compared to what's been communicated earlier.

Operator
42:20 - 42:25

And that was 17,170.

Torbjörn Sköld
42:25 - 42:39

17 and the 17,000. Just for absolute clarity, those are revision arthroplasties with bone infection where a bone graft is needed.

Operator
42:40 - 43:33

Okay. Excellent. Thank you. And then on NTAP, finally. And I heard it, I think, correctly that. That you expect the trauma NTAP will. It will be more challenging than when we initially received it for osteomyelitis. Which makes perfect sense. But do you think that the net impact here short term will be a negative driver, or do you expect the underlying osteomyelitis procedures to carry on even though you don't have the NTAP on those particular procedures?

Torbjörn Sköld
43:35 - 44:38

Well, to clarify, we were discussing the market dynamics. The difference is between some of them. There is a bone infection. And in trauma, when we talk about the value of the intact. Specifically, I think that it should not have so much impact when penetrating the market in bone infection cases, but when we are discussing trauma, especially open trauma, the circumstances require evaluation of the risks versus costs. And here, NTAP is taking away the cost aspect. So potentially, the NTAP for open trauma has a greater value. But again, it remains to be seen over time. It has been valid since the 1st of October. So that is after Q3. And we don't have the data to back that up. But we honestly believe that it has the potential to have a bigger impact than before, focusing solely on bone infection.

Operator
44:40 - 44:42

Okay. Thank you very much.

Torbjörn Sköld
44:47 - 44:51

The next question comes from Maria Vara from Stifel. Please go ahead.

Operator
44:53 - 45:28

Good morning, and thank you for taking my questions. Just a couple of them. I think, you know, we see the extremities as the near-term opportunity. What's going to drive growth for the company for many years? But of course, I think we haven't dedicated much time to the opportunity in the spine during the Q&A session. So I just wanted to maybe get some thoughts on how the recruitment of sales reps is going and any kind of guidance on the contribution we could see from the first quarter launch as well as from 2026. There is a bone infection.

Torbjörn Sköld
45:29 - 47:15

Yes, that's a good question. And I think to put spine in perspective, spine is clearly a very interesting area for BONESUPPORT for the long term. But we also want to be realistic in the short term. We will likely see a much bigger uptake from revision arthroplasty than we will in spine. But spine is an important, strategic, and large opportunity for us. The approach that we take is to first launch spine with segment BVF to build the market. So we are going to have a relatively focused launch. So we're not going to go fully nationwide to all the accounts. At the same time, we want to take a focused approach with certain distributors that we already work with, and some new distributors that specialize in spine, ensuring that we build the right clinical evidence and validated surgical techniques over time. And then, of course, the big strategic play for us is to enter the spine market with CERAMENT G. But that, of course, requires market approval. But we see a couple of good scenarios ahead of us. So the question is not if, but about how and when. And that's why we engage in discussions with the FDA in the near term, to ensure that we feel comfortable with the right way to market and that we are able to execute on that.

Operator
47:16 - 47:52

Okay. That's helpful. And then if we think about the profile of the sales commissions in the US, you know, we see a little bit of an increase with respect to the US revenue for Q3. If I'm not wrong, it's 35% in respect to the US sales. How should we think about this percentage changing over time, especially as the US launch progresses? I mean, there's not much of an investment there, but still, there is something. So if you can guide whether we could think about this same range with respect to revenue or if any major changes here will be appreciated.

Torbjörn Sköld
47:53 - 48:37

Yeah, well, thank you, Maria. Again, in the short to mid-term, you can expect some of the increase in Q3 to be mainly related to short-term volatility. The commission level remains stable. There is no change in commission levels. There are a few performance-related aspects in the commission structure. That's why there can be some volatility between quarters. But in general, it should remain consistent with the commission rates. Plus other fees that are involved. I mean between 34% and 35% over time. And we don't see any inroads into changing that structure.

Operator
48:39 - 48:42

Okay. Thank you so much. That's it from my side.

Torbjörn Sköld
48:44 - 48:45

But that, of course, requires market approval.

Operator
48:48 - 48:53

The next question comes from Oskar Bergman from Redeye. Please go ahead.

Torbjörn Sköld
48:55 - 49:11

Hello, Torbjörn. And welcome. I know you've answered a lot of questions. I only have a few more for you guys. So first off, on your current base of US assignment users. Is there any noteworthy crossover to spine surgery among these?

Operator
49:15 - 49:25

Very limited, I would say. Well, of course, when we have hospital accounts where we have both surgeons on the extremity side and on the spine side.

Torbjörn Sköld
49:25 - 49:26

Yeah, but it's very clear.

Operator
49:26 - 49:55

Very. We have a list of hospitals and a list of surgeons that we are addressing. And so, we ensure that we reach the right surgeons to build additional clinical data and validation before we expand our efforts. With that, we also work very focused on which distributors and sales reps we're contracting.

Torbjörn Sköld
49:57 - 50:18

Okay, and I'm just wondering if you can elaborate a bit more on the situation regarding possible pushback on prices, both for customers in the bone action segment and in trauma. Has this been a factor for customers either not signing up or perhaps deciding to discontinue during this quarter?

Operator
50:19 - 51:14

Well, cost price is always a discussion. We're operating in a commercial environment and so forth. However, so far, it has had no impact on the listing and continued growth of listed hospitals. We encounter this as well, as I mentioned in the call, as part of our go-stop-go strategy, we have hospitals where surgeries are becoming frequent, and high usage often evokes a reaction from hospital administration. So, of course, that's part of daily life. But so far, we don't see a general pushback on price.

Torbjörn Sköld
51:15 - 51:25

Okay, so those efforts in training and education on the health economic benefits are preventing customers from perhaps signing off, essentially.

Operator
51:26 - 51:37

For now, and again, that's also the reason why we're confident with the approach that we're using, and that's why we will also continue to invest in additional methods and enhanced economic resources.

Torbjörn Sköld
51:39 - 51:52

All right. Thanks.

Operator
51:52 - 52:33

From my perspective, what I see is that there's plenty of room to grow in current markets, current products, and current clinical indications. And now, I might be wrong on that, but all the data that I've seen so far after a couple of weeks indicates that we're just scratching the surface on these three main segments that we prioritize short term, which are foot and ankle trauma and revision arthroplasty. And then, of course, longer term, we're entering the spine market. So I think there's plenty of room to grow. Room to grow.

Torbjörn Sköld
52:34 - 52:48

All right. Just two more quick questions. I suspect you're in a hurry. The geographical reach in the US. Are you at a good capacity already in the different key regions, or are there any initiatives that you will accelerate?

Operator
52:49 - 53:22

I mean, the US, as you well know, is our most important market, both from a growth and profitability point of view. It is our number one priority. I think we have good coverage, but that doesn't mean that we will not continue to invest. We are investing in Q3. We will continue to invest because if we are not investing, we are not taking advantage of the potential that we have. So, I don't think it's a coverage issue. It's about making sure we invest to address the potential we have in terms of increasing the penetration.

Torbjörn Sköld
53:23 - 53:31

Okay. So there's no specific region in the US where you feel like, okay, we should really focus on this specific region.

Operator
53:32 - 53:51

I mean, when we look at the map, of course, we have certain regions where we think our penetration and market share are lower. But that's not something that we disclose on this call. But on a high level, we will continue to invest to ensure that we increase the penetration in the US. And certain regions have a higher priority than others.

Torbjörn Sköld
53:52 - 54:10

Okay. This is my final question. You are quickly accumulating a lot of cash, over 220 million since Q3 last year. Will you perhaps present some sort of plan on how you aim to deploy this growing mountain of cash at your Capital Markets Day in the spring?

Operator
54:11 - 54:46

I think, as Tony mentioned during the call, and sorry for all the technical interruptions, that's an area where we owe the market some clearer communication and the Capital Markets Day in the springtime. It's a good opportunity to do that in the shorter term. Again, some of this gives us the comfort to continue investing in the business. We believe in the business. We think we are doing the right things. We see strong confirmations in the Q3 report on the work that we're doing. And the capital helps us to continue investing in this.

Torbjörn Sköld
54:46 - 55:25

And it gives us the freedom to operate in a way that allows us to take advantage of all the opportunities we see in the three priority segments, plus spine, as well as on longer-term strategic initiatives and scenarios that we are, of course, also working on. But more on that in the Capital Market's Day this spring. So unfortunately, we now have to close this call. We're coming to an end. Again, thank you all for attending. And also from our side, we apologize for the technical issues that you experienced, and we thank you for your patience.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…